[Study of Ro 4-8347 administered from the 5th to 25th of the cycle to women with regular cycle with ovulation].
D015065:17-Hydroxycorticosteroids / Q000652:urine*; D015068:17-Ketosteroids / Q000652:urine*; D000726:Androgen Antagonists; D001831:Body Temperature / Q000187:drug effects; D003864:Depression, Chemical; D004967:Estrogens / Q000652:urine*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D007986:Luteinizing Hormone / Q000037:antagonists & inhibitors*; D010053:Ovary / Q000032:analysis; D010060:Ovulation / Q000187:drug effects*; D011276:Pregnanediol / Q000037:antagonists & inhibitors / Q000652:urine*; D011372:Progestins / Q000008:administration & dosage*; D013268:Stimulation, Chemical
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D000726:Androgen Antagonists; D004967:Estrogens; D011372:Progestins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D011276:Pregnanediol
Etude du Ro 4-8347 administré du 5e au 25e jour du cycle à des femmes présentant des cycles réguliers avec ovulation.